Clarivate Plc reports developments in data, analytics and workflow software for academia and government, intellectual property, and life sciences and healthcare. Its news commonly covers earnings, subscription and recurring revenue trends, cash flow and leverage actions, and progress under its operating improvement initiatives.
Company updates also focus on AI-enabled research and decision-support products, including Web of Science Research Intelligence, Nexus Connect, Cortellis Regulatory Intelligence, Derwent-based patent analytics and other Clarivate data assets. Recurring announcements address institutional research intelligence, academic library workflows, regulatory intelligence for life sciences teams, intellectual property benchmarks and investor conference appearances.
Clarivate Plc (NYSE: CLVT), a global provider of transformative intelligence, announced its participation in two investor conferences in June 2024.
CEO Jonathan Gear will present at the William Blair Growth Stock Conference on June 4 at 2:00 p.m. Central Time (3:00 p.m. Eastern Time), accessible via live webcast.
CFO Jonathan Collins will present at the Stifel Cross Sector Insight Conference on June 5 at 3:35 p.m. Eastern Time, also accessible via live webcast.
Replays of both webcasts will be available on Clarivate's investor relations website for 90 days.
On May 22, 2024, Clarivate released its 'Medical Technologies to Watch in 2024' report, spotlighting five breakthrough medical technologies projected to generate significant clinical and commercial impact. These technologies include pulsed field ablation devices for atrial fibrillation, advanced diabetes care devices, neurostimulation devices, surgical robotics, and renal denervation technology for hypertension management. The report forecasts these technologies will generate over $1 billion in market value or achieve double-digit growth within the next five years. Challenges such as shifting service sites, global supply chain issues, and evolving policy landscapes are also acknowledged.
Clarivate has released its Trademark Filing and Litigation Trends 2024 Report, highlighting a return to stability and growth in trademark filing activity globally. The report analyzes trademark registers from the U.S., EU, U.K., Mainland China, Japan, and South Korea, revealing that 2023 exhibited stable trademark filing activities surpassing pre-COVID levels, especially in the U.S., EU, and South Korea. The U.K. demonstrated sustained high growth, while Japan and Mainland China showed slower growth. Key sectors driving trademark applications include retail and business services, technology, and technical services. Mainland China and U.S. applicants led in filing applications across multiple regions, with L'Oreal emerging as a leading filer in several registers.
Clarivate has launched the Trademark Watch Analyzer, an AI-enhanced solution aimed at improving trademark protection. Announced at the 2024 International Trademark Association Annual Meeting, this tool integrates global trademark and case law data, in-house IP expertise, and advanced AI technology. The analyzer covers trademark datasets from 258 countries and 191 trademark registers, along with data from over 7 million trademark litigation cases. This system automates key trademark watching tasks and prioritizes result sets, allowing clients to rank results based on success or opposition chances. According to CompuMark data, trademark applications have doubled since 2014, increasing the need for vigilant trademark monitoring. Gordon Samson, Clarivate's President of Intellectual Property, emphasized that this solution helps clients save time, cost, and resources while ensuring global trademark monitoring and automated alerts.
Clarivate released the 2024 Non-Practicing Entity (NPE) Global Litigation Report, detailing NPE enforcement activities and patent challenges globally. The U.S., Germany, and Mainland China lead in NPE litigation cases, with the U.S. accounting for 97.2% from 2018-2023, Germany 1.8%, and China 0.4%. The report notes a 43% decrease in U.S. NPE cases, a 600% increase in China, and a decline in Germany from 2018. The report found that overall NPE infringement actions declined globally from 2012-2019 and stabilized at around 2,000 cases per year starting in 2020. It also highlights that NPEs face higher patent invalidation rates compared to non-NPEs, indicating potential patent quality issues.
OMRON, a leading automation company, has selected IPfolio™, an intellectual property management software from Clarivate Plc (NYSE: CLVT), to transform their IP operations. The solution aims to maximize operational efficiency by leveraging IP data and analytical insights, enabling OMRON to make smarter decisions and plan strategically. With IPfolio, OMRON can better manage its IP assets, increase productivity, and streamline processes.
Clarivate reported first-quarter 2024 results with revenues of $621.2 million, a 1.3% decrease. The net loss attributable to ordinary shares was $93.8 million. Adjusted net income decreased by 20.9% to $103.5 million. The company reaffirmed its outlook for 2024.
Clarivate Plc (NYSE: CLVT) has introduced Epidemiology Intelligence™, a new solution that provides biopharma companies with epidemiology, incidence, and prevalence data, along with claims-based population insights, to enhance market sizing and patient population analysis. The tool aims to address limitations in traditional research methods, offering unique insights for accurate forecasting and identification of niche populations. The launch signifies Clarivate's commitment to delivering comprehensive solutions to the life sciences and healthcare industries.
Clarivate Plc (NYSE:CLVT) has launched the enhanced Cortellis CMC Intelligence solution with a post-approval variations module. This update allows pharmaceutical companies to streamline regulatory tracking and optimize life cycle management for small molecules and biologics. The module covers regulatory changes across 64 countries, reducing tracking time and increasing submission rates. Cortellis CMC Intelligence aims to simplify CMC regulatory dossier submissions, automate monitoring through alerts, and offer comprehensive lifecycle information for drugs and biologics.
Clarivate Plc declared a quarterly dividend of $1.3125 per share on its 5.25% Series A Mandatory Convertible Preferred Shares, payable on June 3, 2024. Each Preferred Share will convert into ordinary shares based on the VWAP of Clarivate's shares. The conversion rate depends on the VWAP value, with specific ratios based on price levels. Shareholders of record on May 15, 2024, will receive the dividend.